RenovoRx Receives First Purchase Orders for its FDA-Cleared RenovoCath® Delivery System [Yahoo! Finance]
RenovoRx, Inc. (RNXT)
Company Research
Source: Yahoo! Finance
The system is designed for targeted delivery of fluids in the peripheral vascular system and has shown a 100-fold improvement in surrounding tissue concentration compared to conventional intravenous delivery. Over ten medical institutions have initiated the process for RenovoCath purchase orders, and the company is exploring further revenue-generating activities. RenovoRx is also continuing its Phase III clinical trial for its investigational drug-device product candidate utilizing the RenovoCath device for the treatment of locally advanced pancreatic cancer. Over Ten Medical Institutions Nationwide have Initiated RenovoCath Purchase Process, Further Accelerating Commercialization Strategy RenovoRx Estimates Initial Target Market Size for RenovoCath of Several Hundred Million Dollars in Annual Sales Global Medical Device Commercial Leader, Richard Stark, Joining RNXT as Commercial Advisor LOS ALTOS, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc (“RenovoRx” or the “Co
Show less
Read more
Impact Snapshot
Event Time:
RNXT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RNXT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RNXT alerts
High impacting RenovoRx, Inc. news events
Weekly update
A roundup of the hottest topics
RNXT
News
- RenovoRx Initiates Patient Enrollment at SCRI Oncology Partners for Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic CancerGlobeNewswire
- RenovoRx CEO to Host Investor Fireside Chat on Tuesday, December 17th at 4:30 p.m. ET [Yahoo! Finance]Yahoo! Finance
- RenovoRx, Inc. (NASDAQ: RNXT) had its price target raised by analysts at Ascendiant Capital Markets from $8.25 to $9.00. They now have a "buy" rating on the stock.MarketBeat
- RenovoRx CEO to Host Investor Fireside Chat on Tuesday, December 17th at 4:30 p.m. ETGlobeNewswire
- RenovoRx Receives First Purchase Orders for its FDA-Cleared RenovoCath® Delivery SystemGlobeNewswire
RNXT
Analyst Actions
- 12/10/24 - Ascendiant Capital
RNXT
Sec Filings
- 11/14/24 - Form 8-K
- 11/13/24 - Form 10-Q
- 10/2/24 - Form 4
- RNXT's page on the SEC website